Chapter 6: Neoplasia

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

We take complex source material,

break it down and give you the insights you need.

Today we're tackling a really big one, neoplasia, essentially the fundamental pathophysiology of cancer.

It's absolutely critical.

I mean, globally, cancer is still the second leading cause of death for adults and maybe even more sobering.

It's the second leading cause of death for school age kids in the U .S.

That's significant context.

It really is.

And that context shapes our mission today.

We're digging into the core mechanisms,

the cellular processes that go awry.

We're talking about how normal cell differentiation and growth just lose control, become uncoordinated, autonomous.

That's neoplasia, right?

New growth.

Exactly.

And that term autonomous is key.

This isn't like normal adaptation like muscle growth, hypertrophy, or, you know, cells multiplying due to hormones, hyperplasia, neoplastic growth.

It just ignores the usual rule book.

It's outside those normal regulatory controls.

Okay, so to understand how the rules get broken, we first need to understand the rules themselves.

Our deep dive today will follow cancer's life story.

We'll start with the cell cycle failures, then look at benign versus malignant tumors.

The causes, both genetic and environmental.

Now it shows up clinically, the symptoms.

And then, of course, diagnosis, treatment, and a specific look at childhood cancers, which are quite different.

Right.

So let's start at the very beginning, the cellular level.

Normal tissue renewal involves what?

Three key processes?

Three main things, yeah.

Cell proliferation, that's division.

Cell differentiation and specialization.

And apoptosis programmed cell death, getting rid of damaged cells.

And cancer basically finds ways to mess with this balance.

Profoundly.

It particularly exploits the cell cycle.

That orderly sequence a cell goes through.

G1S, G2M.

G1 is growth and protein synthesis.

S is DNA replication.

G2 preps for mitosis.

M is the actual division.

Correct.

And then there's G0, the resting phase.

Some cells, like skin, cycle constantly.

Others, like neurons, are permanently in G0, but cancer cells.

They often find ways to skip G0, or they just ignore the signals telling them to stop dividing.

So the cell cycle has checkpoints, right?

Like quality control steps.

Absolutely crucial.

Think of G1S and G2M checkpoints.

They make sure everything's okay.

Like, is the DNA copied correctly before moving to the next phase?

And how does the cell manage that?

What's the

It's this elegant interaction between proteins called cyclins and enzymes called cyclin -dependent kinases, or CDKs.

Cyclins get made during specific phases, bind to CDKs, and activate them.

That's the G0 signal.

Okay, so cyclins activate CDKs to push the cycle forward.

What puts the brakes on if something's wrong?

That's where CDK inhibitors, or CKIs, come in.

If there's, say, DNA damage, CKIs block the cyclin -CDK complex, pausing the cycle for repairs.

And this is where modern medicine really intersects, right?

Targeting these regulators.

Definitely.

Manipulating CDKs and CKIs, especially at that critical G1S transition point, is the whole idea behind some of the newer targeted cancer therapies.

It's about hitting the accelerator, or the brakes, specifically in cancer cells, hopefully with less collateral damage than older chemo.

Fascinating.

Okay, moving beyond the cycle itself, let's talk about the body's reserve pool stem cells.

Right.

Stem cells have two amazing properties.

Self -renewal, they can divide lots while staying undifferentiated, and potency, their potential to become different cell types.

We go from totipotent, the fertilized egg, down to pluripotent, multipotent, and finally, unipotent stem cells.

Correct.

And this links directly to cancer through the concept of cancer stem cells, sometimes called tumor initiating cells, or TICs.

Ah, the cells that can restart a tumor even after treatment.

Exactly.

They've been found in breast cancer, AML, others.

These TICs might be the original cell targeted by the initial cancer causing mutation.

It implies that treatment needs to not just shrink the tumor bulk, but specifically eliminate these resilient TICs to prevent recurrence.

A huge challenge.

Okay, so we've seen the cellular basis.

Now let's look at the structures they form.

Benign versus malignant neoplasms.

How do we even name these things?

The naming usually follows the tissue of origin plus a suffix.

Benign tumors often end in OMA.

Think adenoma for a glandular tumor or osteoma for bone.

And malignant ones.

They use carcinoma if they arise from epithelial tissue like lung, breast, colon cancer, or sarcoma if they come from mid -centimal tissue, bone, muscle connective tissue.

So an octuosarcoma is a malignant bone tumor.

And their characteristics are fundamentally different.

You describe benign tumors as almost polite.

Huh.

Well, they are more orderly.

Benign cells look a lot like the original tissue.

They're well differentiated.

They tend to grow slowly, pushing surrounding tissue aside.

That's growth by expansion.

They're usually localized, often contained within a fibrous capsule.

Generally not deadly unless, you know, their location causes problems like pressure inside the skull.

Malignant tumors, though, are the opposite.

Invasive, disorganized.

Totally.

They're less differentiated, sometimes completely losing resemblance to the tissues.

They don't have that nice capsule.

And they have the potential to metastasize, spreading to distant parts of the body.

You mentioned anaplasia.

Is that graded?

Yes.

Typically graded eye to ghee.

Grade one is well differentiated.

Still looks pretty normal.

Grade fourth is marked anaplasia.

The cells look very primitive, almost embryonic.

It reflects how aggressive the cancer is likely to be.

Let's dig into the hallmarks of these malignant cells.

What makes them tick beyond just uncontrolled growth?

There are specific alterations, right?

Oh, yeah.

A whole suite of bad behaviors.

First, genetic instability.

They accumulate mutations like crazy extra chromosomes, missing bits, rearrangements.

It's genomic chaos.

Then there's growth factor independence.

Right.

They don't wait for external signals to divide.

Sometimes they make their own growth factors or their receptors are just stuck in the on position.

Like estrogen receptor negative breast cancer doesn't need estrogen to grow.

They also ignore personal space.

Completely.

That's loss of contact inhibition.

Normal cells stop dividing when they bump into neighbors.

Cancer cells just pile up, growing rampantly.

And this ties into their ability to spread.

They don't need to be anchored.

That's anchorage independence.

Normal cells need attachment to a surface or matrix to survive and grow.

If they detach, they die a process called anoicus, kind of like cellular homelessness.

Cancer cells overcome this.

They can survive and multiply even when floating free, which is essential for metastasis.

And the final insult,

immortality.

Pretty much.

They achieve this through high levels of an enzyme called telomerase.

See, normal cells have protective caps on chromosome ends called telomeres, which shorten with each division, eventually signaling the cell to stop dividing or die.

Telomerase rebuilds these caps, allowing cancer cells to divide indefinitely.

All these abilities enable invasion and metastasis.

How does spread actually happen?

Several routes.

Direct invasion into adjacent tissues, often sending out crab -like projections because they secrete enzymes that degrade barriers.

They're seeding into body cavities, like ovarian cancer spreading throughout the peritoneum.

And then they're spread via lymphatics or the bloodstream.

Clinically, we look for the sentinel node in lymphatic spread.

Yes.

That's the first lymph node receiving drainage from the tumor.

Biopsying it helps stage cancers like breast cancer and melanoma.

Hematologic spread via blood often follows venous flow.

So gut cancers frequently metastasize to the liver first because blood goes through the portal vein.

And metastasis isn't just random shedding of cells.

It's a complex process.

Highly complex.

Only a select clone of cells within the tumor usually acquires all the necessary traits.

Break loose, survive in circulation, evade the immune system, exit the vessel, and establish a new colony in a distant organ.

It's a tough journey.

What about the speed of growth?

Is the cell cycle just faster?

Not necessarily shorter.

Often it's because a larger proportion of cells are actively dividing what we call a high -growth fraction.

And they don't stop dividing or enter that G0 resting state like normal cells do.

They just keep going.

Okay, we see the chaos.

Where does the initial spark come from?

The etiology,

the genetic and molecular roots?

It starts with genetic damage, mutations, but it's often a combination of that, plus epigenetic changes, modifications that alter gene expression without changing the DNA sequence itself and the influence of the surrounding microenvironment.

Let's talk about the key genes.

The accelerators and brakes metaphor is useful here.

Right.

The accelerators are protoontogenes.

These are normal genes involved in growth signaling.

When mutated, they become overactive oncogenes, driving uncontrolled proliferation.

Classic examples are gene amplifications like HR2Nu in some breast cancers, or chromosomal translocations like the Philadelphia chromosome creating the BCRL oncogene in CML.

And the brakes.

Those are the tumor suppressor genes, or TSGs.

Their job is to inhibit proliferation or trigger cell death if damage is too severe.

Think RB gene, or the very famous TP53 gene.

When TSGs lose function, the brakes are off.

And this is where the two -hit hypothesis often applies.

Exactly.

Especially for TSGs.

You typically need both copies of a TSG to be inactivated two mutational hits to completely lose its function.

If you inherit one mutated copy, like in familial retinoblastoma and RB mutation, you're already halfway there.

Just one more somatic mutation in the other copy in a retinal cell, and the cancer can develop.

You mentioned epigenetics too.

How does that play a role?

Epigenetic mechanisms like methylation can silence tumor suppressor genes without actually mutating the DNA sequence.

It's like turning off the gene switch.

This is increasingly recognized as a major factor.

So defects in DNA repair, growth signaling, apoptosis evasion without blood supply, angiogenesis.

Crucial.

A tumor can't grow beyond a tiny size, maybe a millimeter or two, without its own blood supply to deliver nutrients and oxygen.

Tumors actively secrete factors like VEGF to stimulate new blood vessel growth.

Interestingly,

functional TP53 normally inhibits angiogenesis.

Losing TP53 promotes it.

That's why anti -angiogenesis drugs like bevacizumab, which targets VEGF, are a key treatment strategy trying to starve the tumor.

This whole process is multi -step, isn't it?

Initiation, promotion.

Yes.

The classical model is initiation, irreversible DNA damage by a carcinogen, promotion, accelerated growth of the initiated cell, often driven by hormones or inflammation, potentially reversible, and progression.

Acquiring more mutations, becoming invasive and metastatic.

And it's influenced by host factors and the environment.

Heredity we touched on with BRCA genes.

Right.

And hormones can drive growth in cancers like breast and prostate.

The immune system is also critical.

The immune surveillance hypothesis suggests our immune cells normally detect and destroy nascent cancer cells.

When immunity declines with AIDS or immunosuppressant drugs, cancer risk goes up.

T cells, NK cells, macrophages are all involved.

What about external carcinogens?

Chemicals, radiation, viruses.

Huge factors.

Chemical carcinogens include things in tobacco, smoke.

Tobacco has both initiators and promoters.

Diet plays a role aflatoxins in moldy peanuts, compounds from charring meat.

Alcohol is another big one.

Radiation, both ionizing like from atomic bombs or industrial exposure, and UV radiation from sunlight causing skin cancer, damages DNA.

And viruses.

Several are strongly linked.

DNA viruses like HPV causing cervical cancer, Epstein -Barr virus, EBV linked to Burkitt lymphoma, hepatitis B, HPV to liver cancer.

And RNA viruses too, like HDLV1 causing a type of T cell leukemia.

They often work by inserting viral oncogenes or disrupting host genes.

Okay, let's shift to how this manifests in the patient, the clinical picture.

Obviously, there's direct tissue damage.

Yes.

The tumor mass can compress vital structures, erode blood vessels causing bleeding like blood in the stool from pollen cancer, or invade nerves causing pain.

It can also obstruct tubes, like the bowel.

And effusions fluid build up in body cavities, like pleural effusion in the chest or ascites in the abdomen are common signs, often from tumor cells irritating surfaces or blocking drainage.

Beyond the local effects, there are systemic symptoms caused by altered metabolism.

Cachexia is a major one.

The cancer anorexia cachexia syndrome.

It's a profound wasting loss of fat and muscle.

And crucially, you can't just fix it by feeding the person more.

It seems driven by a combination of the tumor's high metabolic rate, it gobbles glucose, and systemic inflammation caused by cytokines like TNF alpha, IL -1, and IL -6, released by the tumor or the body's response to it.

That sounds exhausting, which likely explains the profound fatigue.

Debilitating fatigue and weakness, not relieved by rest, is a very common symptom, sometimes even an early one.

Anemia is also frequent due to blood loss, chemo, or inflammatory cytokines suppressing red blood cell production.

And then there are the really strange ones, the perineoplastic syndromes.

Right, these are symptoms that aren't directly caused by the tumor mass itself, or its metastases.

They often happen because the tumor cells start producing hormones or other signaling molecules they shouldn't be, like a lung tumor might secrete ADH, causing water retention, and low sodium, or ACTH, causing Cushing's syndrome symptoms.

It's the tumor acting like an endocrine gland gone rogue.

Okay, given this complexity, how do we approach screening, diagnosis, and treatment?

Screening aims to catch cancer early and asymptomatic.

People think mammograms, pap smears, colonoscopies.

Early detection generally offers the best chance for cure.

For diagnosis, what are the main tools?

We use tumor markers, substances like PSA for prostate, CEA for colon, AFP for liver, or germ cell tumors.

But you have to be cautious.

They're often better for monitoring tuitant response or recurrence than for initial diagnosis or screening.

The definitive diagnosis usually requires a tissue biopsy getting a sample of the suspicious cells for microscopic examination.

Cytology, like a PAP test, looks at shed cells.

And advanced techniques.

Things like immunohistochemistry use antibodies to detect specific proteins in the biopsy sample.

This can help pinpoint the cancer's origin, if it's metastatic, or identify prognostic markers like hormone receptors.

MicroRA technology lets us look at the expression of thousands of genes at once, helping classify tumors and predict outcomes.

Once diagnosed, staging and grading are key.

Yes.

Grading, as we said, is based on cell differentiation, I to IV anaplasia.

Staging describes the extent of disease spread.

The universal system is TNM.

T for primary tumor size and local invasion, N for regional lymph node involvement, and M for distant metastasis.

Staging is critical for choosing treatment and predicting prognosis.

And treatment itself is usually multimodal.

Often, yes.

Combining surgery, radiation, chemotherapy, hormonal therapy, and newer biotherapies or immunotherapies.

The goal can be cure, control, or palliation.

Symptom relief.

Surgery is the oldest method.

Radiation uses energy to damage DNA.

Right.

The idea is that rapidly dividing cancer cells are more susceptible to DNA damage than most normal cells.

It can be delivered via external beam, internal implants, brachytherapy, or systemic radioisotopes.

What makes radiation less effective sometimes?

A major factor is hypoxia.

Cells and poorly oxygenated parts of a tumor are much more resistant to radiation damage because oxygen is needed to create the most damaging free radicals.

Chemotherapy is systemic, hitting cells throughout the body.

Correct.

It's generally most effective against tumors with a high growth fraction, lots of cells actively dividing.

The drugs typically target DNA synthesis, RNA synthesis, or mitosis.

We classify them as cell cycle specific, hitting cells in a particular phase like methotrexid and S phase, or non -specific acting throughout the cycle like alkylating agents.

The big challenge with chemo is toxicity, right?

The nadir.

Yes, the nadir is the point of lowest blood counts after a chemo cycle, usually 7 -14 days later.

That's when the risk of infection from low neutrophils, anemia, and bleeding from low platelets is highest due to bone marrow suppression.

Nausea, vomiting, and hair loss are also common because chemo hits other rapidly dividing cells in the gut and hair follicles.

Though anti -nausea drugs like the 5 -HT3 antagonists have made a huge difference there.

And then there's hormonal therapy and biotherapy.

Hormonal therapy blocks hormone signals that drive certain cancers, like tamoxifen blocking estrogen receptors and breast cancer.

Biotherapy, or immunotherapy, aims to harness the patient's own immune system to fight the cancer, using things like monoclonal antibodies or checkpoint inhibitors.

Finally, let's touch on childhood cancers.

They're different beasts.

Very different.

Much rarer than adult cancers, thankfully, but still a leading cause of death by disease in kids.

And they tend to involve different tissues, hematopoietic system, leukemias, lymphomas, nervous system, bone, kidneys, rather than the epithelial tissues common in adults.

We see more embryonal tumors.

Yes, tumors arising from embryonic tissue remnants,

like Wilm's tumor of the kidney, retinoblastoma in the eye, or neuroblastoma.

Neuroblastoma is particularly common and often secretes catecholamines.

Treatment outcomes have improved dramatically, right?

Around 85 % survival overall now.

Incredible progress, yes.

Chemotherapy is often the main modality.

But this success brings a major new challenge.

The late sequelae, the long -term effects of treatment on survivors.

That's the crucial point for modern care, isn't it?

Absolutely.

These kids survive, but the treatments can leave lasting damage.

Cranial radiation, for example, is linked to cognitive deficits and growth hormone problems.

Chest radiation increases risks for later breast cancer and heart disease.

Certain chemo drugs, like alkylating agents, can cause infertility or secondary cancers later.

Anthracyclines can damage the heart.

We're saving lives, but sometimes at a significant long -term cost.

So we've covered a lot of ground.

From the breakdown of the cell cycle, the sneaky ways cancer cells survive and thrive, the concept of cancer stem cells.

Through metastasis, the genetic drivers like oncogenes and faulty tumor suppressors, the environmental triggers.

The systemic effects like cachexia, how we diagnose and stage using TNM, the different treatment approaches.

And ending with the unique aspects and the long -term challenges faced by childhood cancer survivors.

It really highlights how neoplasia is this complex interplay of cellular malfunction,

genetics, environment, and the body's own response.

Precisely.

And that brings us to our final thought for you, building on that issue of childhood cancer survival.

We've gotten incredibly good at

achieving that 85 % survival rate,

but the focus has to shift now.

It's not just about cure, but about the quality of that survival.

So the question becomes, beyond just targeting the cancer itself, what specific molecular pathways damaged by the life -saving therapies do we need to understand and potentially target to prevent or mitigate the devastating late effects like cognitive decline, heart failure, and secondary cancers as these survivors grow into adulthood?

How do we optimize their future?

A profound challenge indeed.

Thank you for joining us on this deep dive.